US$ 20.74
glp-1 vomiting class action in kentucky Zepbound Lawsuit [2026] Frontiers | GLP-1 and Underlying
Description
However, discontinuation is often followed by partial weight regain within months, reinforcing that patients generally experience these medicines as chronic therapies rather than short term cures
![glp-1 vomiting class action in kentucky Zepbound Lawsuit [2026] Frontiers | GLP-1 and Underlying](https://www.frontiersin.org/files/Articles/721198/xml-images/fendo-12-721198-g001.webp)
Youre on a biologic
![glp-1 vomiting class action in kentucky Zepbound Lawsuit [2026] Frontiers | GLP-1 and Underlying](https://levinlaw.com/wp-content/uploads/2026/02/GLP-1-header-landing-1920x1080.jpg)
Rosen, a research scientist in the Division of General Internal Medicine
![glp-1 vomiting class action in kentucky Zepbound Lawsuit [2026] Frontiers | GLP-1 and Underlying](https://bloximages.newyork1.vip.townnews.com/wdrb.com/content/tncms/assets/v3/editorial/e/d1/ed175930-e581-11ef-a992-8baa188f781d/67a651da43691.image.jpg?crop=1919%2C1007%2C0%2C36&resize=1200%2C630&order=crop%2Cresize)
Clinical data shows that without concurrent lifestyle changes or continued treatment, weight regain typically begins within weeks to months after stopping GLP-1 therapy
![glp-1 vomiting class action in kentucky Zepbound Lawsuit [2026] Frontiers | GLP-1 and Underlying](https://injurylawyer.com/wp-content/uploads/2023/12/iStock-1665778558-300x200.jpg)
A meta-analysis found that liraglutide reduced binge frequency by approximately 1.28 fewer episodes per week compared to placebo ( Choudhury et al., Clinical Therapeutics, 2026 )